Skip to content

Author

V. Katanaev

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Comprehensive phytochemical study of Galianthe thalictroides: isolation of three new compounds, structural revision of β-carbolines, and evaluation of cytotoxic and anti-wnt activities

The medicinal plant G. thalictroides (K. Schum.) E. L. Cabral has been traditionally used in Midwestern Brazil for cancer treatment and prevention. Previous studies demonstrated that the chloroform fraction of its roots exhibits significant cytotoxic activity against cancer cell lines. Phytochemical investigation of this fraction led to the isolation of four cytotoxic compounds, including two β-carboline alkaloids and two cyclopeptides, supporting the traditional use of this species. However, several minor metabolites detected in this active fraction were not obtained in sufficient quantities for complete structural elucidation or biological evaluation. In this context, the present study aimed to expand the chemical characterization of Galianthe thalictroides , with a particular focus on previously unresolved metabolites. Additionally, the study sought to explore other extracts and preparations, including the traditional decoction, to provide a more comprehensive understanding of the phytochemical profile and its potential biological relevance. The roots of G. thalictroides were extracted with ethanol and a traditional water decoction was prepared in parallel. The ethanolic extract was subjected to liquid/liquid partitioning with hexane, chloroform, and ethyl acetate. The extracts, fractions, and traditional decoction were analyzed by ultra-high-performance liquid chromatography coupled with high-resolution mass spectrometry (UHPLC-HRMS/MS) to establish a comprehensive metabolite profile and generate a molecular networking (MN). The chloroform fraction was purified using medium-pressure liquid chromatography (MPLC-UV) followed by semi-preparative HPLC. Structural characterization of the isolated compounds was achieved through UV, Electronic Circular Dichroism, Nuclear Magnetic Resonance, and High-Resolution Mass Spectrometry data. The chemical shifts and coupling constants of β-carboline derivatives were calculated using the CT web application, which performs a complete Quantum Mechanical Spectral Analysis. Finally, the isolated compounds were evaluated for activity in a dose-dependent manner using BT-20 triple-negative breast cancer cells. This was conducted to determine their cytotoxic potencies and specific Wnt-inhibitory activities via a TopFlash reporter assay. Using this approach, 26 compounds were isolated from the chloroform fraction and fully characterized. Notably, this study led to the discovery of two new cyclopeptides and one new β-carboline alkaloid, which represent the most significant and original contributions of this work. In addition, the structures of two previously reported β-carboline alkaloids from this species were revised. Molecular networking–guided MS profiling of the extracts, fractions, and traditional decoction enabled the annotation of 13 additional metabolites, thereby expanding the known chemical diversity of G. thalictroides . Biological evaluation confirmed the cytotoxic activity of known compounds and revealed new active analogues. Bouvardins exhibited strong cytotoxicity (IC 50 0.25–14.00 µM), while anthraquinones and β-carboline alkaloids showed moderate activity (IC 50 23–110 μM and 65–193 μM, respectively). Mechanistic studies revealed that β-carboline derivative 24 selectively inhibited the Wnt signaling pathway (IC 50 ≈ 40 µM), whereas its analogue ( 25 ) was inactive. Overall, this study significantly advances the chemical and biological understanding of G. thalictroides by integrating compound isolation, structural characterization, and biological evaluation. The discovery of novel bioactive compounds, together with evidence of pathway-specific effects, highlights the plant’s potential as a source of structurally diverse and pharmacologically relevant metabolites for anticancer research.

Patrícia de Oliveira Figueiredo, O. Kirchhoffer, L. Marcourt et al. · 0 citations
#gene editing Review Sep 2026

Novel and Emerging Therapies for Childhood-Onset Movement Disorders.

Childhood-onset movement disorders comprise a heterogeneous group of rare conditions with substantial unmet therapeutic needs. Recent advances in disease gene discovery, mechanistic modeling, and translational platforms have accelerated the development of targeted therapies and enabled innovative clinical trial designs for small patient populations. To review novel and emerging therapies for childhood-onset movement disorders, with a focus on pharmacologic strategies, disease-modifying approaches, and patient-centered precision therapies. We surveyed the literature, major conference proceedings, and expert networks to identify therapies approved, in clinical development, or supported by compelling preclinical data between 2022 and 2025. We focused on small molecules and genetic therapies for conditions in which movement disorders represent a prominent clinical feature. Small molecules were categorized as repurposed or novel drugs, whereas genetic therapies included gene replacement, gene editing, and RNA-based expression modulation. Drug repurposing approaches have shown promise in disorders related to the GNAO1, ATP1A3, ATM, and ADCY5 genes. Novel small molecules have advanced for Friedreich's ataxia and Tourette's syndrome. Gene replacement therapies have demonstrated clinical benefit in select neurotransmitter disorders, whereas gene editing strategies have entered preclinical development for ATP1A3-related disease. Antisense oligonucleotide therapies have yielded encouraging early results across several conditions with prominent movement disorder phenotypes, including KIF1A-related neurological disorder, Angelman syndrome, SCN2A-related neurodevelopmental disorder, and ataxia-telangiectasia. Precision-based therapeutic strategies are rapidly reshaping the treatment landscape for childhood-onset movement disorders. Continued progress will depend on rigorous phenotyping, careful ethical oversight, and deliberate efforts to promote equitable global access to emerging therapies. © 2026 International Parkinson and Movement Disorder Society.

C. D. de Gusmao, V. Katanaev, Laura Silveira-Moriyama et al. · 0 citations
Aug 2026

MYC-driven BYSL overexpression promotes hepatocellular carcinoma by suppressing nucleolar stress and inactivating the RPL5/RPL11-MDM2-p53 pathway.

BYSL gene encodes the bystin-like (BYSL) protein, a nucleolar protein involved in eukaryotic ribosome biogenesis and essential for 40S ribosomal subunit synthesis. Although BYSL upregulation has been implicated in hepatocellular carcinoma, its mechanistic contribution to tumor progression remains undefined. We observed that BYSL is consistently upregulated across multiple cancer types and is associated with adverse clinicopathological features and poor prognosis, with the strongest clinical relevance observed in hepatocellular carcinoma through the integrative transcriptomic and proteomic analyses. BYSL-knockout suppresses malignant phenotypes, including proliferation, migration, and invasion, and induced G1/S arrest and apoptosis. Mechanistically, loss of BYSL disrupts nucleolar homeostasis and reduces global protein synthesis, thereby activating the RPL5/RPL11-MDM2-p53 axis, leading to p53 stabilization and tumor suppression. Importantly, MYC directly bound to the BYSL promoter and transcriptionally activated its expression, whereas co-targeting BYSL and MYC produced more synergistic antitumor effects than either intervention alone. Collectively, our study reveals that BYSL acts as a pivotal downstream mediator of MYC-regulated ribosome biogenesis and promotes hepatocellular carcinoma progression. Our findings suggest that BYSL may represent a potential therapeutic target for hepatocellular carcinoma; nevertheless, additional in vivo preclinical studies are warranted to validate its translational prospects.

Heyuan Zhao, Hui-Ying Liu, Xia Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.